This is an amended filing
Voronoi, Inc. VRN110755 Phase 1/2 Trial Target Raised to 355 Subjects, Australia Amendment Filed
AI summary · Not investment advice
Following an Australian protocol update, the VRN110755 Phase 1/2 trial target was changed from around 255 to around 355 subjects in an amendment application.
Commentary
AI commentary · Not investment advice
What happened
Voronoi has applied in Australia for approval to raise the target number of participants in its VRN110755 Phase 1/2 trial from 255 to about 355. The change follows an update to the trial protocol (the trial plan) in Australia. The trial targets advanced non-small cell lung cancer (NSCLC).
In the company's terms
The study combines Phase 1 and Phase 2 in one trial. It can run for up to 6 years, including long-term follow-up. Its registration number is NCT07699328.
What changes for shareholders
The company notified the Australian ethics committee (HREC) of the change application. The materials do not say whether it has been approved or give any later schedule.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
V